NETRI has announced the commercial launch of its NeuroFluidics™ MEA line, developed in collaboration with Axion BioSystems and compatible with the company’s flagship Maestro MultiElectrode Array (MEA) systems. The new product line offers a range of ready-to-use compartmentalized microfluidic devices with an integrated MEA layer, providing high-throughput organs-on-chip platforms for disease research and drug discovery in neurology, dermatology, and other fields.
NETRI has announced the commercial launch of its NeuroFluidics™ MEA line, developed in collaboration with Axion BioSystems and compatible with the company’s flagship Maestro MultiElectrode Array (MEA) systems. The new product line offers a range of ready-to-use compartmentalized microfluidic devices with an integrated MEA layer, providing high-throughput organs-on-chip platforms for disease research and drug discovery in neurology, dermatology, and other fields.
/PRNewswire/ The Global Organ On Chip Market is Segmented by Type (Liver-on-a-chip, Kidney-on-a-chip, Lung-on-a-chip, Heart-on-a-chip, Intestine-on-a-chip,.